PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk
Introduction: Abnormal blood cholesterol levels in patients with increased cardiovascular risk have a worse prognosis for patient survival. Treating dyslipidemia is important because it can improve patient comfort and safety. It sometimes happens that currently used drugs to lower cholesterol are n...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nicolaus Copernicus University in Toruń
2024-12-01
|
| Series: | Quality in Sport |
| Subjects: | |
| Online Access: | https://apcz.umk.pl/QS/article/view/56299 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846127874556297216 |
|---|---|
| author | Radosław Szydłowski Magdalena Bodera Hanna Porwolik Agata Porwolik Patrycja Pabis Agnieszka Porwolik Dominik Rabstein Piotr Gościniewicz |
| author_facet | Radosław Szydłowski Magdalena Bodera Hanna Porwolik Agata Porwolik Patrycja Pabis Agnieszka Porwolik Dominik Rabstein Piotr Gościniewicz |
| author_sort | Radosław Szydłowski |
| collection | DOAJ |
| description |
Introduction: Abnormal blood cholesterol levels in patients with increased cardiovascular risk have a worse prognosis for patient survival. Treating dyslipidemia is important because it can improve patient comfort and safety. It sometimes happens that currently used drugs to lower cholesterol are not effective - patients develop tolerance or experience serious side effects. For this reason, scientists are looking for new drugs with a different mechanism of action. An example of such a group of drugs are PCSK9 inhibitors used to treat dyslipidemia. In this paper, we will look at the effectiveness of currently used PCSK9 inhibitors, but also at the potential risks associated with their use.
Material and methods: We searched for materials for this work in the Pubmed and Google Scholar databases using the keywords: "dyslipidemia", "cardiovascular disease", "PCSK9 inhibitors", "statins". Then we analyzed the selected materials.
Aim of the study: Evaluation of the
Conclusion: PCSK9 inhibitors are drugs that are very effective in lowering low-density lipoprotein (LDL-C), while reducing cardiovascular risk and potentially having long-lasting effects. Scientists are looking for new PCSK9 inhibitors with different mechanisms of action, which will be an even more effective therapy in lowering LDL-C.
|
| format | Article |
| id | doaj-art-31e7f0a64afa48f7885e4e59531850b3 |
| institution | Kabale University |
| issn | 2450-3118 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Nicolaus Copernicus University in Toruń |
| record_format | Article |
| series | Quality in Sport |
| spelling | doaj-art-31e7f0a64afa48f7885e4e59531850b32024-12-11T08:09:18ZengNicolaus Copernicus University in ToruńQuality in Sport2450-31182024-12-013610.12775/QS.2024.35.56299PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular riskRadosław Szydłowski0Magdalena Bodera1Hanna Porwolik2Agata Porwolik3Patrycja Pabis4Agnieszka Porwolik5Dominik Rabstein6Piotr Gościniewicz7Professor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, PolandProfessor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, PolandProfessor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, PolandProfessor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, PolandProfessor Zbigniew Religa Student Scientific Association at the Department of Biophysics, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, Jordana 19, 41-808 Zabrze, PolandSilesia Orthodontics, Juliusza Słowackiego 13, 40-094 Katowice, Poland"YOU CLINIC RABSTEIN" SPOLKA JAWNA, Kłodnicka 10, 40-702, KatowiceWSB University, 41-300 Dabrowa Gornicza, Zygmunta Cieplaka 1c Introduction: Abnormal blood cholesterol levels in patients with increased cardiovascular risk have a worse prognosis for patient survival. Treating dyslipidemia is important because it can improve patient comfort and safety. It sometimes happens that currently used drugs to lower cholesterol are not effective - patients develop tolerance or experience serious side effects. For this reason, scientists are looking for new drugs with a different mechanism of action. An example of such a group of drugs are PCSK9 inhibitors used to treat dyslipidemia. In this paper, we will look at the effectiveness of currently used PCSK9 inhibitors, but also at the potential risks associated with their use. Material and methods: We searched for materials for this work in the Pubmed and Google Scholar databases using the keywords: "dyslipidemia", "cardiovascular disease", "PCSK9 inhibitors", "statins". Then we analyzed the selected materials. Aim of the study: Evaluation of the Conclusion: PCSK9 inhibitors are drugs that are very effective in lowering low-density lipoprotein (LDL-C), while reducing cardiovascular risk and potentially having long-lasting effects. Scientists are looking for new PCSK9 inhibitors with different mechanisms of action, which will be an even more effective therapy in lowering LDL-C. https://apcz.umk.pl/QS/article/view/56299PCSK9 inhibitorscardiovascular diseasedyslipidemia |
| spellingShingle | Radosław Szydłowski Magdalena Bodera Hanna Porwolik Agata Porwolik Patrycja Pabis Agnieszka Porwolik Dominik Rabstein Piotr Gościniewicz PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk Quality in Sport PCSK9 inhibitors cardiovascular disease dyslipidemia |
| title | PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk |
| title_full | PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk |
| title_fullStr | PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk |
| title_full_unstemmed | PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk |
| title_short | PCSK9 inhibitors – new era of dyslipidemia treatment - effectiveness in reducing low-density lipoprotein (LDL-C) and cardiovascular risk |
| title_sort | pcsk9 inhibitors new era of dyslipidemia treatment effectiveness in reducing low density lipoprotein ldl c and cardiovascular risk |
| topic | PCSK9 inhibitors cardiovascular disease dyslipidemia |
| url | https://apcz.umk.pl/QS/article/view/56299 |
| work_keys_str_mv | AT radosławszydłowski pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk AT magdalenabodera pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk AT hannaporwolik pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk AT agataporwolik pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk AT patrycjapabis pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk AT agnieszkaporwolik pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk AT dominikrabstein pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk AT piotrgosciniewicz pcsk9inhibitorsneweraofdyslipidemiatreatmenteffectivenessinreducinglowdensitylipoproteinldlcandcardiovascularrisk |